Quick answer
Revolution Medicines, Inc. (RVMD) reported revenue of $0.0M and net loss of $1.13B for the fiscal year ended 2025-12-31, per its 10-K filed with the SEC on 2026-02-25.
Data as of 2025-12-31. Source: SEC EDGAR XBRL company facts (10-K/10-Q filings)
| Fiscal year | Revenue | Net income | Long-term debt |
|---|---|---|---|
| 2025 (FY ending 2025-12-31) | $0.0M | -$1.13B | — |
| 2024 (FY ending 2024-12-31) | $0.0M | -$600.1M | — |
| 2023 (FY ending 2023-12-31) | $11.6M | -$436.4M | — |
| 2022 (FY ending 2022-12-31) | $35.4M | -$248.7M | — |
| 2021 (FY ending 2021-12-31) | $29.4M | -$187.1M | — |
| 2020 (FY ending 2020-12-31) | $43.0M | -$108.2M | — |
| 2019 (FY ending 2019-12-31) | $50.0M | -$47.7M | — |
| 2018 (FY ending 2018-12-31) | $20.2M | -$41.8M | — |
Related
- RS revenue, net income and debt history (Reliance, Inc.)
- RSG revenue, net income and debt history (Republic Services, Inc.)
- RTX revenue, net income and debt history (Rtx Corporation)
- RVTY revenue, net income and debt history (Revvity, Inc)
- RYAN revenue, net income and debt history (Ryan Specialty Holdings, Inc.)
- S revenue, net income and debt history (Sentinelone, Inc)
- SAIA revenue, net income and debt history (Saia, Inc.)
- SAIL revenue, net income and debt history (SailPoint, Inc.)
Last updated 2026-10-16. Data only, not financial or tax advice.